Pioglitazone: a review of its use in type 2 diabetes mellitus.
作者： John Waugh , Gillian M Keating , Greg L Plosker , Stephanie Easthope , Dean M Robinson
DOI: 10.2165/00003495-200666010-00005
关键词:
摘要: Pioglitazone is an antihyperglycaemic agent that, in the presence of insulin resistance, increases hepatic and peripheral insulin sensitivity, thereby inhibiting hepatic gluconeogenesis …
springer.com
sci-hub.se 
researchgate.net 参考文章(91)
Ian W. Campbell, Antidiabetic drugs present and future: will improving insulin resistance benefit cardiovascular risk in type 2 diabetes mellitus? Drugs. ,vol. 60, pp. 1017- 1028 ,(2000) , 10.2165/00003495-200060050-00004
D Einhorn, J Rosenstock, S Yu, K Hershon, N B Glazer, Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. International Journal of Clinical Practice. ,vol. 56, pp. 251- 257 ,(2002)
Millard H. Lambert, Steven A. Kliewer, Timothy M. Willson, PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ∞ AND METABOLIC DISEASE ,(2001)
Charles G. Gegick, MD, FACP, Michael D. Altheimer, MD, FACE, Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice. Endocrine Practice. ,vol. 7, pp. 162- 169 ,(2001) , 10.4158/EP.7.3.162
Andreas Pfützner, Nikolaus Marx, Georg Lübben, Matthias Langenfeld, Daniel Walcher, Thomas Konrad, Thomas Forst, Improvement of Cardiovascular Risk Markers by Pioglitazone Is Independent From Glycemic Control Journal of the American College of Cardiology. ,vol. 45, pp. 1925- 1931 ,(2005) , 10.1016/J.JACC.2005.03.041
André Scheen, Thiazolidinediones and liver toxicity. Diabetes & Metabolism. ,vol. 27, pp. 305- 313 ,(2001)
I.W. Campbell, Long-term glycaemic control with pioglitazone in patients with type 2 diabetes International Journal of Clinical Practice. ,vol. 58, pp. 192- 200 ,(2004) , 10.1111/J.1368-5031.2004.0108.X
Timothy M. Willson, Millard H. Lambert, Steven A. Kliewer, Peroxisome proliferator-activated receptor γ and metabolic disease Annual Review of Biochemistry. ,vol. 70, pp. 341- 367 ,(2001) , 10.1146/ANNUREV.BIOCHEM.70.1.341
WA Scherbaum, B Göke, null and the German Pioglitazone Study Group, None, Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study. Hormone and Metabolic Research. ,vol. 34, pp. 589- 595 ,(2002) , 10.1055/S-2002-35421
C. J. de Souza, M. Eckhardt, K. Gagen, M. Dong, W. Chen, D. Laurent, B. F. Burkey, Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes. ,vol. 50, pp. 1863- 1871 ,(2001) , 10.2337/DIABETES.50.8.1863